Skip to main content
Top
Published in: BMC Gastroenterology 1/2014

Open Access 01-12-2014 | Research article

MELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathy

Authors: Valérie Martel-Laferrière, Caitlin Homberger, Kian Bichoupan, Douglas T Dieterich

Published in: BMC Gastroenterology | Issue 1/2014

Login to get access

Abstract

Background

Hepatic encephalopathy (HE) represents a significant burden to the healthcare system. The aim of this study was to determine factors influencing the hospital length of stay among patients hospitalized with HE.

Methods

A data warehouse query was performed to identify 316 patients with a first hospitalization during which HE occurred, between April 2010 and February 2012. Baseline and hospitalization characteristics were collected with IRB approval. A negative binomial multivariable model was used to control for potential confounders on the length of hospitalization.

Results

Median age was 59 years, and 60.4% of admitted patients were male. The median MELD score was 22 (IQR: 17-28). Median length of stay was 8 days (IQR: 3.25-14.25). After controlling for MELD score, female gender (2.2 days; p = 0.04), being initially admitted for a reason other than HE (liver-related: 7.6 days; p < 0.01 and non liver-related 10.7 days; p < 0.01) and receiving antibiotics other than rifaximin (10.5 days; p < 0.01) were associated with longer length of stay whereas hepatitis C (-3.1 days; p < 0.01) was associated with a shorter length of stay.

Conclusions

MELD score, gender, use of antibiotics other than rifaximin, reason for admission and hepatitis C are predictors readily available in clinic that can help identify patients at risk for longer length of stay.
Literature
1.
go back to reference Poordad FF: Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007, 25 (Suppl 1): 3-9. doi:10.1111/j.1746-6342.2006.03215.x [published Online First: Epub Date]CrossRefPubMed Poordad FF: Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007, 25 (Suppl 1): 3-9. doi:10.1111/j.1746-6342.2006.03215.x [published Online First: Epub Date]CrossRefPubMed
2.
go back to reference Stepanova M, Mishra A, Venkatesan C, Younossi ZM: In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol. 2012, 10 (9): 1034-1041. 10.1016/j.cgh.2012.05.016. e1 doi:10.1016/j.cgh.2012.05.016 [published Online First: Epub Date]CrossRefPubMed Stepanova M, Mishra A, Venkatesan C, Younossi ZM: In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol. 2012, 10 (9): 1034-1041. 10.1016/j.cgh.2012.05.016. e1 doi:10.1016/j.cgh.2012.05.016 [published Online First: Epub Date]CrossRefPubMed
3.
go back to reference Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT: Hepatic encephalopathy–definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002, 35 (3): 716-721. 10.1053/jhep.2002.31250. doi:10.1053/jhep.2002.31250 [published Online First: Epub Date]CrossRefPubMed Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT: Hepatic encephalopathy–definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002, 35 (3): 716-721. 10.1053/jhep.2002.31250. doi:10.1053/jhep.2002.31250 [published Online First: Epub Date]CrossRefPubMed
4.
go back to reference Kim WR, Brown RS, Terrault NA, El-Serag H: Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002, 36 (1): 227-242. 10.1053/jhep.2002.34734. doi: 10.1053/jhep.2002.34734 [published Online First: Epub Date]CrossRefPubMed Kim WR, Brown RS, Terrault NA, El-Serag H: Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002, 36 (1): 227-242. 10.1053/jhep.2002.34734. doi: 10.1053/jhep.2002.34734 [published Online First: Epub Date]CrossRefPubMed
5.
go back to reference El Khoury AC, Klimack WK, Wallace C, Razavi H: Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat. 2012, 19 (3): 153-160. 10.1111/j.1365-2893.2011.01563.x. doi:10.1111/j.1365-2893.2011.01563.x [published Online First: Epub Date]CrossRefPubMed El Khoury AC, Klimack WK, Wallace C, Razavi H: Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat. 2012, 19 (3): 153-160. 10.1111/j.1365-2893.2011.01563.x. doi:10.1111/j.1365-2893.2011.01563.x [published Online First: Epub Date]CrossRefPubMed
6.
go back to reference Berman K, Tandra S, Forssell K, Vuppalanchi R, Burton JR, Nguyen J, Mullis D, Kwo P, Chalasani N: Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol. 2011, 9 (3): 254-259. 10.1016/j.cgh.2010.10.035. doi:10.1016/j.cgh.2010.10.035 [published Online First: Epub Date]CrossRefPubMed Berman K, Tandra S, Forssell K, Vuppalanchi R, Burton JR, Nguyen J, Mullis D, Kwo P, Chalasani N: Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol. 2011, 9 (3): 254-259. 10.1016/j.cgh.2010.10.035. doi:10.1016/j.cgh.2010.10.035 [published Online First: Epub Date]CrossRefPubMed
7.
go back to reference Jalan R, Fernandez J, Wiest R, Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, Stadlbauer V, Gustot T, Bernardi M, Canton R, Albillos A, Lammert F, Wilmer A, Mookerjee R, Vila J, Garcia-Martinez R, Wendon J, Such J, Cordoba J, Sanyal A, Garcia-Tsao G, Arroyo V, Burroughs A, Gines P: Bacterial infections in cirrhosis: a position statement based on the EASL special conference 2013. J Hepatol. 2014, 60 (6): 1310-1324. 10.1016/j.jhep.2014.01.024. doi:10.1016/j.jhep.2014.01.024 [published Online First: Epub Date]|CrossRefPubMed Jalan R, Fernandez J, Wiest R, Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, Stadlbauer V, Gustot T, Bernardi M, Canton R, Albillos A, Lammert F, Wilmer A, Mookerjee R, Vila J, Garcia-Martinez R, Wendon J, Such J, Cordoba J, Sanyal A, Garcia-Tsao G, Arroyo V, Burroughs A, Gines P: Bacterial infections in cirrhosis: a position statement based on the EASL special conference 2013. J Hepatol. 2014, 60 (6): 1310-1324. 10.1016/j.jhep.2014.01.024. doi:10.1016/j.jhep.2014.01.024 [published Online First: Epub Date]|CrossRefPubMed
8.
go back to reference Hung TH, Lay CJ, Chang CM, Tsai JJ, Tsai CC, Tsai CC: The effect of infections on the mortality of cirrhotic patients with hepatic encephalopathy. Epidemiol Infect. 2013, 1-8. doi:10.1017/S0950268813000186 [published Online First: Epub Date]| Hung TH, Lay CJ, Chang CM, Tsai JJ, Tsai CC, Tsai CC: The effect of infections on the mortality of cirrhotic patients with hepatic encephalopathy. Epidemiol Infect. 2013, 1-8. doi:10.1017/S0950268813000186 [published Online First: Epub Date]|
9.
go back to reference Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK: A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013, 108 (9): 1458-1463. 10.1038/ajg.2013.219. doi:10.1038/ajg.2013.219 [published Online First: Epub Date]CrossRefPubMed Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK: A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013, 108 (9): 1458-1463. 10.1038/ajg.2013.219. doi:10.1038/ajg.2013.219 [published Online First: Epub Date]CrossRefPubMed
10.
go back to reference Sharma P, Sharma BC, Sarin SK: Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2010, 22 (5): 526-531. 10.1097/MEG.0b013e3283341b7d. doi:10.1097/MEG.0b013e3283341b7d [published Online First: Epub Date]CrossRefPubMed Sharma P, Sharma BC, Sarin SK: Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2010, 22 (5): 526-531. 10.1097/MEG.0b013e3283341b7d. doi:10.1097/MEG.0b013e3283341b7d [published Online First: Epub Date]CrossRefPubMed
11.
go back to reference Shawcross DL, Sharifi Y, Canavan JB, Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, Auzinger G, Bernal W, Wendon JA: Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol. 2011, 54 (4): 640-649. 10.1016/j.jhep.2010.07.045. doi:10.1016/j.jhep.2010.07.045 [published Online First: Epub Date]CrossRefPubMed Shawcross DL, Sharifi Y, Canavan JB, Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, Auzinger G, Bernal W, Wendon JA: Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol. 2011, 54 (4): 640-649. 10.1016/j.jhep.2010.07.045. doi:10.1016/j.jhep.2010.07.045 [published Online First: Epub Date]CrossRefPubMed
12.
go back to reference Vilstrup H, Amodio P, Bajaj J, Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P: Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014, 60 (2): 715-735. 10.1002/hep.27210. doi:10.1002/hep.27210 [published Online First: Epub Date]CrossRefPubMed Vilstrup H, Amodio P, Bajaj J, Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P: Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014, 60 (2): 715-735. 10.1002/hep.27210. doi:10.1002/hep.27210 [published Online First: Epub Date]CrossRefPubMed
13.
go back to reference Wiegand J, Kuhne M, Pradat P, Mossner J, Trepo C, Tillmann HL: Different patterns of decompensation in patients with alcoholic vs non-alcoholic liver cirrhosis. Aliment Pharmacol Therapeut. 2012, 35 (12): 1443-1450. 10.1111/j.1365-2036.2012.05108.x. doi:10.1111/j.1365-2036.2012.05108.x [published Online First: Epub Date]CrossRef Wiegand J, Kuhne M, Pradat P, Mossner J, Trepo C, Tillmann HL: Different patterns of decompensation in patients with alcoholic vs non-alcoholic liver cirrhosis. Aliment Pharmacol Therapeut. 2012, 35 (12): 1443-1450. 10.1111/j.1365-2036.2012.05108.x. doi:10.1111/j.1365-2036.2012.05108.x [published Online First: Epub Date]CrossRef
Metadata
Title
MELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathy
Authors
Valérie Martel-Laferrière
Caitlin Homberger
Kian Bichoupan
Douglas T Dieterich
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2014
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-14-185

Other articles of this Issue 1/2014

BMC Gastroenterology 1/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.